Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18actual
Sites
7
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-23 | actual | When the study began enrolling |
| Primary completion | 2026-01-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-14 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- B Precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Intervention
- Drug: Blinatumomab — also filed as Blincyto®
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Complete Remission (CR)
measured Up to 84 days
Number of Participants with CR with Partial Recovery of Peripheral Blood Counts (CRh)
measured Up to 84 days
Publications
- PMID 41671463 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed